



# Cancer Control in Europe: Finding Sustainable Solutions

---

13 - 14 December 2021



Co-funded by  
the Health Programme  
of the European Union

# WP5 PARTNERS

---

## Cancer Society of Finland (CSF)

### 1. PARTICIPATING PARTNERS IN WP 5

**Finland CSF WP leader and THL, competent authority**

**Associated partners: preparation and planning, active participation, crucial for the successful events and reporting**

**Hungary (OOI), Italy (ISS), Czechia (UZIS), France (INCA), Norway (Cancer registry), Slovenia (OIL), Bulgaria (NCPHA), Croatia (CIPH), Lithuania (SAM, VUHKS), Malta (MFM), Netherlands (RIVM), Serbia (IPHS), Spain (ICO, Fisabio, screening partners), Romania (INSP), Greece (7HCR, Crete), Germany (BMG/DKFZ)**

**International Agency for Research on Cancer (European Code Against Cancer)  
Association of European Cancer Leagues (organization of policy conferences)**

**Active collaborating partners**

**Thank you!**

# OUTCOMES: EARLY DIAGNOSIS

---

## Cancer Society of Finland (CSF)

### **EARLY DETECTION: Possibilities of early diagnosis**

- **Survey of barriers (M1):** Survey on 4 selected cancer types (oral, prostate, skin, breast ) and six barriers with inequality and importance. 153 completed answers from 31 countries; 77 from iPAAC consortium (M1)
- **Thematic conference in May 2019 in Budapest with 70 participants**
- **Report Insight and effectiveness of early diagnosis**  
<https://www.ipaac.eu/res/file/outputs/wp5/insight-effectiveness-early-diagnosis.pdf>

# OUTCOMES: CANCER SCREENING

## Cancer Society of Finland (CSF)

### **EARLY DETECTION: Population-based cancer screening programmes**

- Report on innovations, including benefit and harm from risk-stratified screening (M2)
- Technical meeting (40 participants), thematic conference in December 2019 with about 80 participants in December 2019 in Helsinki
- Conference report *New openings of cancer screening in Europe*  
<https://www.ipaac.eu/res/file/outputs/wp5/new-openings-cancer-screening-europe.pdf>
- Web tool on governance and quality assurance on cancer screening based on CANCON plus updates > ipaac.eu > WP5 and  
<https://cancerregistry.fi/screening/ipaac-cancer-screening-infograph/>

# WEB TOOL FOR QUALITY ASSURANCE

Governance is the key to good planning.

## Cancer screening

Welcome! Here we describe the recommended governance structure for the cancer screening programmes for breast, cervical and colorectal cancer screening. The national governance must establish adequate legal, financial, and organizational frameworks for effective cancer screening, integrating quality assurance at all appropriate levels.



This website arises from iPAAC Joint Action (2018-2021) and is mostly based on the book European Guide on Quality Improvement in Comprehensive Cancer Control (Albrecht et al. 2018). Read the whole chapter on policy recommendations on governance, organization and evaluation of cancer screening:

Cancer screening

<https://cancerregistry.fi/screening/ipaac-cancer-screening-infograph/>

All the references:

# OUTCOMES: CANCER PREVENTION



Cancer Society of Finland (CSF)

**EUROPEAN CODE AGAINST CANCER (ECAC) (M3): Sustainability and monitoring of the European Code Against Cancer: Recommendations**

**4/2020 - 2 days online with over 100 participants**

<https://doi.org/10.1016/j.canep.2021.101933>

**Cancer prevention and health promotion –2/2021 online with over 150 participants**

**Cancer prevention in the 2020s report <https://www.ipaac.eu/res/file/outputs/wp5/cancer-prevention-in-2020s.pdf>**

**Cancer prevention in clinical practice (7HCR)**

**<https://www.ipaac.eu/res/file/outputs/wp5/cancer-prevention-through-physical-activity.pdf>**

**Health in All Policies (CSF) background paper and update in the conference report**



## Cross-cutting actions, covering all tasks

- Policy brief on advancing early detection  
<https://www.ipaac.eu/res/file/outputs/wp5/early-detection-of-cancer-policy-brief.pdf>
- Contest of Best Practices Tackling Social Inequalities in Cancer Prevention (Fisabio, Spain) <https://www.ipaac.eu/res/file/20190513-contest/contest-best-practices-report.pdf>
- Social innovations and implementation focus
- Co-creational and open conferences > multi-disciplinary attendance

---

## Cancer Society of Finland (CSF)

### 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

**Early diagnosis: better awareness and evidence-base, further research, vulnerable populations, health systems**

**Cancer screening programmes: EBCP: Council recommendation (2003) update and guidelines for existing recommended screening programmes (breast, cervix, colorectal) > risk-adaptation step-by-step modifications with quality assurance, existing programmes > improved implementation in MSs**

**Potential new programmes and the role of genomics > further research, systematic reviews and health-economic evaluations needed**



# CANCER PREVENTION: FUTURE USE



---

## Cancer Society of Finland (CSF)

**Cancer prevention> integration, comprehensive cancer control, capacity building measures, adaptation to environmental challenges (diet and nutrition), tobacco, alcohol, physical activity, vaccinations**

**Known strategies of prevention ECAC: Roadmap towards the 5<sup>th</sup> edition with dissemination and research**

**Monitoring and research of COVID-19 pandemic effects on cancer prevention, early diagnosis and cancer screening programmes**

**iPAAC coordination and partners: Thank you for your excellent support!**



Sciensano

## 1. PARTICIPATING PARTNERS IN WP 6

# GENOMICS IN CANCER CONTROL AND CARE

---



Sciensano

## 2. KEY OUTPUTS & OUTCOMES COMPLETED



Sciensano

## 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

*(Sustainability, long-term impact and continuation Describe the follow-up of the WP outputs/outcomes after the JA ends. How will the impact be ensured and sustained? How will the results be used? Are there any possible synergies/complementarities with other (EU funded) activities that can build on the project results?)*

# CANCER INFORMATION AND REGISTRATION

---

Italian National Institute of Public Health (ISS)

## 1. PARTICIPATING PARTNERS IN WP 7

# CANCER INFORMATION AND REGISTRATION

---

Italian National Institute of Public Health (ISS)

## 2. KEY OUTPUTS & OUTCOMES COMPLETED

Italian National Institute of Public Health (ISS)

## 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

*(Sustainability, long-term impact and continuation Describe the follow-up of the WP outputs/outcomes after the JA ends. How will the impact be ensured and sustained? How will the results be used? Are there any possible synergies/complementarities with other (EU funded) activities that can build on the project results?)*

# CHALLENGES IN CANCER CARE

---

Catalonia Institute of Oncology (ICO)

## PARTICIPATING PARTNERS IN WP 8



# CHALLENGES IN CANCER CARE

---

Catalonia Institute of Oncology (ICO)

## 2. KEY OUTPUTS & OUTCOMES COMPLETED

---

## Catalonia Institute of Oncology (ICO)

### 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

*(Sustainability, long-term impact and continuation Describe the follow-up of the WP outputs/outcomes after the JA ends. How will the impact be ensured and sustained? How will the results be used? Are there any possible synergies/complementarities with other (EU funded) activities that can build on the project results?)*

# INNOVATIVE THERAPIES IN CANCER



---

French National Cancer Institute (INCa)

## PARTICIPATING PARTNERS IN WP 9



# INNOVATIVE THERAPIES IN CANCER

---

[French National Cancer Institute \(INCa\)](#)

## 2. KEY OUTPUTS & OUTCOMES COMPLETED

---

## French National Cancer Institute (INCa)

### 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

*(Sustainability, long-term impact and continuation Describe the follow-up of the WP outputs/outcomes after the JA ends. How will the impact be ensured and sustained? How will the results be used? Are there any possible synergies/complementarities with other (EU funded) activities that can build on the project results?)*

# GOVERNANCE OF INTEGRATED AND COMPREHENSIVE CANCER CARE



---

German Federal Ministry of Health (BMG) and German Cancer Society (DKG)

## 1. PARTICIPATING PARTNERS IN WP 10



# GOVERNANCE OF INTEGRATED AND COMPREHENSIVE CANCER CARE



---

German Federal Ministry of Health (BMG) and German Cancer Society (DKG)

## 2. KEY OUTPUTS & OUTCOMES COMPLETED



# GOVERNANCE OF INTEGRATED AND COMPREHENSIVE CANCER CARE



---

German Federal Ministry of Health (BMG) and German Cancer Society (DKG)

## 3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

*(Sustainability, long-term impact and continuation Describe the follow-up of the WP outputs/outcomes after the JA ends. How will the impact be ensured and sustained? How will the results be used? Are there any possible synergies/complementarities with other (EU funded) activities that can build on the project results?)*





**THANK YOU!**